CY
CYTK.US Cytokinetics Inc
- Market cap
- USD 7.82B
- P/E
- -
- P/B
- 60.31x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CYTK.US undervalued?
Graham numberThe Graham number of Cytokinetics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cytokinetics Inc fundamental analysis
No fundamental analysis for Cytokinetics Inc yet.
Cytokinetics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cytokinetics Inc
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omec…
Full company profileCytokinetics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cytokinetics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 106M | 13.4M | 31.5M | 26.9M | 55.8M | 70.4M | 94.6M | 7.53M | 18.5M | 88.0M | 127M |
| Gross Profit | 46.5M | -76.9M | -57.6M | -59.3M | -41.1M | -89.5M | -146M | -323M | -321M | 77.9M | 118M |
| Operating Income | 18.7M | -113M | -88.9M | -98.9M | -93.9M | -186M | -324M | -496M | -536M | -612M | -707M |
| EBITDA | 19.4M | -109M | -83.5M | -93.0M | -86.8M | -184M | -332M | -457M | -493M | -775M | -683M |
| Net Income | 16.5M | -128M | -106M | -122M | -127M | -215M | -389M | -526M | -590M | -785M | -793M |
| EPS | 0.39 | -2.59 | -1.95 | -2.11 | -1.97 | -2.80 | -4.33 | -5.45 | -5.26 | -6.54 | -5.70 |
| Balance Sheet | |||||||||||
| Total Assets | 170M | 295M | 211M | 290M | 534M | 841M | 1.01B | 824M | 1.40B | 1.42B | 1.82B |
| Total Liabilities | 75.8M | 185M | 185M | 301M | 420M | 597M | 1.12B | 1.21B | 1.54B | 2.08B | 2.15B |
| Shareholders' Equity | 94.4M | 110M | 25.9M | -10.9M | 113M | 244M | -108M | -386M | -135M | -660M | -321M |
| Cash & Short-term Investments | 156M | 269M | 199M | 225M | 464M | 472M | 783M | 615M | 1.08B | 882M | 1.13B |
| Total Debt | 29.9M | 37.0M | 42.4M | 136M | 139M | 270M | 750M | 756M | 789M | 1.28B | 1.27B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 37.0M | -102M | -101M | -90.9M | 8.94M | -143M | -300M | -414M | -396M | -510M | -572M |
| Capital Expenditure | 1.60M | 2.88M | 889K | 2.62M | 11.1M | 48.9M | 11.3M | 1.42M | 3.91M | 24.8M | 14.6M |
| Free Cash Flow | 35.4M | -105M | -102M | -93.5M | -2.11M | -191M | -311M | -416M | -400M | -535M | -587M |
| Ratios | |||||||||||
| ROE | 17.4% | -116.3% | -409.8% | - | -112.3% | -88.3% | - | - | - | - | - |
| ROA | 9.7% | -43.3% | -50.3% | -42.0% | -23.8% | -25.6% | -38.3% | -63.8% | -42.1% | -55.1% | -43.5% |
| Net Profit Margin | 15.5% | -955.9% | -337.4% | -452.9% | -228.0% | -305.7% | -411.2% | -6,988.6% | -3,191.1% | -891.6% | -622.7% |
| Debt to Equity | 0.32x | 0.34x | 1.64x | - | 1.23x | 1.11x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cytokinetics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 18.5M | 0.19 | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:6 on Jun 25, 2013.
Who owns Cytokinetics Inc
- Insiders 0.57%
- Institutions 99.43%
- Public & others 0.00%
- Shares outstanding 139M
- Free float 139M
Top funds holding CYTK.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| T. Rowe Price Capital Appreciation | 6.29M | 4.52% | 0.00% | Sep 2026 |
| Vanguard Health Care Inv | 5.69M | 4.09% | +83.12% | Sep 2026 |
| iShares Core S&P Mid-Cap ETF | 5.00M | 3.59% | +0.05% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 4.45M | 3.19% | +2.87% | Sep 2026 |
| iShares Russell 2000 ETF | 3.42M | 2.46% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 3.13M | 2.25% | +0.17% | Sep 2026 |
| American Funds SMALLCAP World A | 2.62M | 1.89% | -12.42% | Sep 2026 |
| Fidelity OTC | 2.21M | 1.59% | -2.48% | Aug 2026 |
| State Street® SPDR® S&P® Biotech ETF | 2.14M | 1.54% | +2.68% | Oct 2026 |
| Polar Capital Biotech S Inc | 1.81M | 1.30% | 0.00% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 1.74M | 1.25% | -3.00% | Sep 2026 |
| T. Rowe Price Small-Cap Value | 1.72M | 1.23% | +3.38% | Sep 2026 |
| T. Rowe Price Mid-Cap Growth | 1.59M | 1.14% | +10.48% | Sep 2026 |
| Fidelity Small Cap Index | 1.45M | 1.04% | +0.15% | Aug 2026 |
| JNL/T. Rowe Price Capital Appreciation A | 1.45M | 1.04% | 0.00% | Sep 2026 |
| T. Rowe Price Capital Apprec Eq ETF | 1.17M | 0.84% | -0.56% | Oct 2026 |
| iShares Russell 2000 Value ETF | 1.13M | 0.81% | 0.00% | Oct 2026 |
| Polar Capital Healthcare Opports Inc | 1.06M | 0.76% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 1.04M | 0.75% | -0.36% | Oct 2026 |
| State Street® SPDR® S&P MIDCAP 400® ETF | 1.03M | 0.74% | +3.53% | Sep 2026 |
Top institutions holding CYTK.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 20.1M | 14.43% | +21.43% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 18.7M | 13.45% | +6.82% | Jun 2026 |
| Wellington Management Company LLP | 6.93M | 4.98% | -13.46% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 6.71M | 4.82% | +14.85% | Jun 2026 |
| State Street Corp | 6.49M | 4.66% | +13.04% | Jun 2026 |
| Vanguard Capital Management, LLC | 6.12M | 4.39% | +11.46% | Jun 2026 |
| FMR Inc | 5.03M | 3.61% | -53.08% | Jun 2026 |
| venBio Select Advisor LLC | 5.00M | 3.59% | +50.00% | Jun 2026 |
| Bank of America Corp | 4.64M | 3.33% | +48.32% | Jun 2026 |
| Geode Capital Management, LLC | 3.71M | 2.67% | +15.46% | Jun 2026 |
| RTW INVESTMENTS, LLC | 2.86M | 2.06% | +5.18% | Jun 2026 |
| Polar Capital Holdings PLC | 2.25M | 1.62% | +35.66% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 1.96M | 1.41% | +23.65% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.76M | 1.27% | -20.14% | Jun 2026 |
| Capital Research Global Investors | 1.69M | 1.21% | +118.76% | Jun 2026 |
| Northern Trust Corp | 1.65M | 1.18% | +14.27% | Jun 2026 |
| William Blair Investment Management, LLC | 1.60M | 1.15% | +47.43% | Jun 2026 |
| Integral Health Asset Management, LLC | 1.60M | 1.15% | 0.00% | Jun 2026 |
| JPMorgan Chase & Co | 1.59M | 1.14% | +75.80% | Jun 2026 |
| Point72 Asset Management, L.P. | 1.59M | 1.14% | +153.59% | Jun 2026 |
Cytokinetics Inc company profile
- Company name
- Cytokinetics Inc
- Ticker
- CYTK.US
- Exchange
- USA Stocks
- Listed since
- Apr 29, 2004
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 673
- Fiscal year end
- December
- Address
- 350 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
- Phone
- 650 624 3000
- Website
- cytokinetics.com
About Cytokinetics Inc
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Cytokinetics Inc management
10- Mr. Robert I. BlumCEO, President & Director · born 1964
- Mr. Sung H. LeeEVP & CFO · born 1970
- Mr. Jeffrey J. Hessekiel J.D.Executive VP, Chief Legal & Administrative Officer · born 1969
- Dr. Fady Ibraham Malik FACC, M.D., Ph.D.Executive Vice President of Research & Development · born 1964
- Mr. Andrew M. CallosExecutive VP & Chief Commercial Officer · born 1969
- Dr. James H. Sabry M.D., Ph.D.Co-Founder & Chairman of Scientific Advisory Board · born 1958
- Dr. James A. Spudich Ph.D.Co-Founder & Member of Scientific Advisory Board · born 1942
- Ms. Holly LaughlinVP of Accounting & Corporate Controller
- Mr. Steven M. Cook J.D.Senior Vice President of Global Supply Chain Operations & Technical Operations · born 1959
- Mr. Scott R. JordanSenior Vice President of Global Marketing & Commercial Strategy